Kliniken Ostalb gemeinnuetzige kommunale Anstalt des oeffentlichen Rechts

Kliniken Ostalb focuses on blood‑related cancers such as multiple myeloma, Waldenström’s Macroglobulinemia, and various lymphomas including Hodgkin lymphoma, diffuse large B‑cell lymphoma, and mantle cell lymphoma. The trials aim to test new targeted agents, combination regimens, and MRD‑driven approaches to improve response and reduce toxicity.

• Novel BTK inhibitor combinations for B‑cell malignancies
• MRD‑guided treatment strategies in myeloma
• Optimizing first‑line regimens for aggressive lymphomas
• Reducing treatment‑related morbidity in high‑risk hematologic cancers
• Assessing spleen response in myelofibrosis

At the Mutlangen campus, investigators collaborate with academic partners to bring innovative therapies to patients with hematologic malignancies.

Research at the hospital also covers solid tumors such as colon cancer, rectal cancer, gastric and oesophagogastric adenocarcinoma, and hormone‑receptor‑positive HER2‑negative breast cancer. Studies evaluate adjuvant strategies, organ‑preserving protocols, and immunotherapy combinations to enhance cure rates and quality of life.

• Adjuvant ctDNA‑guided therapy for stage II colon cancer
• Organ preservation approaches in locally advanced rectal cancer
• Peri‑operative atezolizumab with FLOT for gastro‑esophageal adenocarcinoma
• Targeted endocrine‑therapy combinations for advanced breast cancer
• Risk‑adapted chemotherapy sequencing after surgery

The multidisciplinary team in Mutlangen integrates surgical, medical‑oncology and radiotherapy expertise to advance treatment for these cancers.

A dedicated program addresses treatment‑related neurotoxicity, most notably chemotherapy‑induced polyneuropathy. Trials test preventive agents and symptom‑relief measures to lower the incidence of grade‑2 or higher neuropathy.

• Preventive analgesic interventions during neurotoxic chemotherapy
• Evaluation of neuroprotective supplements in lymphoma patients
• Quality‑of‑life outcomes for patients with chemotherapy‑related neuropathy

Patients receiving neurotoxic chemotherapy are offered enrollment to help preserve nerve function and daily activities.

The site conducts additional investigations that span multiple disease categories, including studies on tyrosine‑kinase inhibitor discontinuation in chronic myeloid leukemia and novel anti‑cancer immunotherapies. These projects seek to refine treatment duration, improve survival, and personalize care across hematologic and solid‑tumor indications.

• Strategies for safe TKI stop‑attempts in CML patients
• Combination immunotherapy trials for high‑risk lymphoid cancers
• Biomarker‑driven dosing adjustments in chronic leukemias
• Evaluation of novel bispecific antibodies in relapsed disease

With a team of nine investigators, the clinic leverages its central location in Mutlangen to contribute to national and international research networks.